Higher vigilance needed to diagnose and treat MDD

Show simple item record

dc.contributor.author Du Plessis, Ilse
dc.date.accessioned 2016-03-08T06:08:30Z
dc.date.available 2016-03-08T06:08:30Z
dc.date.issued 2015-08
dc.description.abstract Selective serotonin reuptake inhibitors (SSRIs) became the first line of treatment of depressive disorders (MDD) during the eighties and has kept its place in the arsenal of options to treat this common disease. MDD accounts for 4,4% of the total overall global disease burden. en_ZA
dc.description.librarian am2015 en_ZA
dc.description.uri http://www.specialistforum.co.za en_ZA
dc.identifier.citation Du Plessis, I 2015, 'Higher vigilance needed to diagnose and treat MDDs', Specialist Forum, vol. 15, no. 7, pp. 12. en_ZA
dc.identifier.issn 2218-8282
dc.identifier.uri http://hdl.handle.net/2263/51711
dc.language.iso en en_ZA
dc.publisher New Media Publishing en_ZA
dc.rights .© The Specialist Forum en_ZA
dc.subject Treatment en_ZA
dc.subject Disease en_ZA
dc.subject Major depressive disorder (MDD) en_ZA
dc.subject Selective serotonin reuptake inhibitors (SSRIs) en_ZA
dc.title Higher vigilance needed to diagnose and treat MDD en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record